logo

Alexion Pharmaceuticals Inc. (ALXN)



Trade ALXN now with
  Date
  Headline
11/8/2017 4:06:11 PM Alexion Appoints Francois Nader To Its Board Of Directors
11/6/2017 6:30:40 AM Alexion Receives New Japanese Patent For Soliris, Extending Patent Protection Into 2027
11/1/2017 9:26:05 AM Alexion To Present New Phase 1/2 Study Data For ALXN1210
10/27/2017 11:13:27 AM RBC Capital Markets Is Raising Alexion Pharmaceuticals Inc. (ALXN) 4Q17 Estimate To 0.37 From 0.07
10/27/2017 11:13:11 AM RBC Capital Markets Is Lowering Alexion Pharmaceuticals Inc. (ALXN) 4Q17 Rev. Estimate To 879.0 M From 882.0 M
10/27/2017 11:11:07 AM RBC Capital Markets Is Cutting Alexion Pharmaceuticals Inc. (ALXN) 2019 Estimate To 4.67 From 4.91
10/27/2017 11:10:56 AM RBC Capital Markets Is Cutting Alexion Pharmaceuticals Inc. (ALXN) 2018 Estimate To 3.03 From 3.32
10/27/2017 11:10:40 AM RBC Capital Markets Is Raising Alexion Pharmaceuticals Inc. (ALXN) 2017 Estimate To 2.19 From 1.87
10/27/2017 11:10:07 AM RBC Capital Markets Is Lowering Alexion Pharmaceuticals Inc. (ALXN) 2019 Rev. Estimate To 4697.0 M From 4829.0 M
10/27/2017 11:09:52 AM RBC Capital Markets Is Lowering Alexion Pharmaceuticals Inc. (ALXN) 2018 Rev. Estimate To 3907.0 M From 3999.0 M
10/27/2017 11:09:41 AM RBC Capital Markets Is Raising Alexion Pharmaceuticals Inc. (ALXN) 2017 Rev. Estimate To 3520.0 M From 3518.0 M
10/26/2017 6:40:09 AM Alexion Pharmaceuticals Inc. (ALXN) Has Raised Its 2017 EPS Estimate To 5.50 - 5.65 From 5.40 - 5.55
10/26/2017 6:39:50 AM Alexion Pharmaceuticals Inc. (ALXN) Has Raised Its 2017 Revenue Estimate To $3475 Mln - $3525 Mln From $3450 Mln - $3525 Mln
10/26/2017 6:31:18 AM Alexion Q3 Total Revenues $859 Mln, An 8% Increase Year-Over-Year